|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ADAMTS6 |
Gene summary for ADAMTS6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ADAMTS6 | Gene ID | 11174 |
| Gene name | ADAM metallopeptidase with thrombospondin type 1 motif 6 | |
| Gene Alias | ADAM-TS 6 | |
| Cytomap | 5q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0001568 | UniProtAcc | Q5IR90 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11174 | ADAMTS6 | EEC-subject1 | Human | Endometrium | EEC | 2.88e-12 | 4.99e-01 | -0.2682 |
| 11174 | ADAMTS6 | EEC-subject2 | Human | Endometrium | EEC | 1.52e-02 | -9.27e-02 | -0.2607 |
| 11174 | ADAMTS6 | EEC-subject3 | Human | Endometrium | EEC | 1.97e-08 | -1.80e-01 | -0.2525 |
| 11174 | ADAMTS6 | EEC-subject4 | Human | Endometrium | EEC | 1.53e-02 | -1.68e-01 | -0.2571 |
| 11174 | ADAMTS6 | GSM5276934 | Human | Endometrium | EEC | 1.27e-07 | -2.21e-01 | -0.0913 |
| 11174 | ADAMTS6 | GSM5276935 | Human | Endometrium | EEC | 6.39e-04 | -1.97e-01 | -0.123 |
| 11174 | ADAMTS6 | GSM5276937 | Human | Endometrium | EEC | 1.78e-04 | -2.23e-01 | -0.0897 |
| 11174 | ADAMTS6 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.32e-07 | -2.46e-01 | -0.1869 |
| 11174 | ADAMTS6 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 4.09e-04 | -2.35e-01 | -0.1875 |
| 11174 | ADAMTS6 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 6.16e-07 | -2.28e-01 | -0.1883 |
| 11174 | ADAMTS6 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 6.78e-08 | 4.45e-01 | -0.1934 |
| 11174 | ADAMTS6 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 8.79e-11 | -2.12e-01 | -0.1917 |
| 11174 | ADAMTS6 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 5.04e-09 | -1.45e-01 | -0.1916 |
| 11174 | ADAMTS6 | ATC09 | Human | Thyroid | ATC | 4.41e-17 | 6.18e-01 | 0.2871 |
| 11174 | ADAMTS6 | ATC11 | Human | Thyroid | ATC | 2.95e-18 | 1.95e+00 | 0.3386 |
| 11174 | ADAMTS6 | ATC12 | Human | Thyroid | ATC | 2.23e-73 | 1.87e+00 | 0.34 |
| 11174 | ADAMTS6 | ATC13 | Human | Thyroid | ATC | 9.50e-14 | 2.87e-01 | 0.34 |
| 11174 | ADAMTS6 | ATC1 | Human | Thyroid | ATC | 6.77e-17 | 6.71e-01 | 0.2878 |
| 11174 | ADAMTS6 | ATC2 | Human | Thyroid | ATC | 2.40e-15 | 1.33e+00 | 0.34 |
| 11174 | ADAMTS6 | ATC3 | Human | Thyroid | ATC | 3.73e-38 | 2.28e+00 | 0.338 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000165512 | Endometrium | EEC | urogenital system development | 69/2168 | 338/18723 | 1.70e-06 | 5.18e-05 | 69 |
| GO:007200112 | Endometrium | EEC | renal system development | 63/2168 | 302/18723 | 2.24e-06 | 6.59e-05 | 63 |
| GO:000182212 | Endometrium | EEC | kidney development | 59/2168 | 293/18723 | 1.44e-05 | 2.87e-04 | 59 |
| GO:003019812 | Thyroid | ATC | extracellular matrix organization | 152/6293 | 301/18723 | 8.63e-10 | 2.24e-08 | 152 |
| GO:004306212 | Thyroid | ATC | extracellular structure organization | 152/6293 | 302/18723 | 1.17e-09 | 2.94e-08 | 152 |
| GO:004522912 | Thyroid | ATC | external encapsulating structure organization | 152/6293 | 304/18723 | 2.11e-09 | 5.08e-08 | 152 |
| GO:000182222 | Thyroid | ATC | kidney development | 146/6293 | 293/18723 | 5.81e-09 | 1.28e-07 | 146 |
| GO:000165522 | Thyroid | ATC | urogenital system development | 164/6293 | 338/18723 | 7.92e-09 | 1.70e-07 | 164 |
| GO:007200122 | Thyroid | ATC | renal system development | 149/6293 | 302/18723 | 9.48e-09 | 1.99e-07 | 149 |
| GO:000327912 | Thyroid | ATC | cardiac septum development | 56/6293 | 103/18723 | 1.14e-05 | 1.11e-04 | 56 |
| GO:000320512 | Thyroid | ATC | cardiac chamber development | 79/6293 | 161/18723 | 3.39e-05 | 2.80e-04 | 79 |
| GO:00608401 | Thyroid | ATC | artery development | 48/6293 | 100/18723 | 1.97e-03 | 9.52e-03 | 48 |
| GO:0035904 | Thyroid | ATC | aorta development | 30/6293 | 58/18723 | 3.31e-03 | 1.48e-02 | 30 |
| GO:0060976 | Thyroid | ATC | coronary vasculature development | 24/6293 | 46/18723 | 7.13e-03 | 2.82e-02 | 24 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ADAMTS6 | SNV | Missense_Mutation | novel | c.1891N>A | p.Pro631Thr | p.P631T | Q9UKP5 | protein_coding | deleterious(0.04) | possibly_damaging(0.484) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| ADAMTS6 | SNV | Missense_Mutation | novel | c.1748N>T | p.Arg583Ile | p.R583I | Q9UKP5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ADAMTS6 | SNV | Missense_Mutation | c.894N>G | p.Ile298Met | p.I298M | Q9UKP5 | protein_coding | deleterious(0.05) | benign(0.088) | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| ADAMTS6 | SNV | Missense_Mutation | c.893N>A | p.Ile298Lys | p.I298K | Q9UKP5 | protein_coding | deleterious(0) | possibly_damaging(0.794) | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| ADAMTS6 | SNV | Missense_Mutation | c.1051N>A | p.Asp351Asn | p.D351N | Q9UKP5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0BO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ADAMTS6 | insertion | Frame_Shift_Ins | novel | c.1145_1146insT | p.Glu382AspfsTer3 | p.E382Dfs*3 | Q9UKP5 | protein_coding | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | CR | |||
| ADAMTS6 | insertion | Nonsense_Mutation | novel | c.2974_2975insAAAATTAAAAGAGAAATAGAATAACCGATAGAGATCTGAACAAG | p.Ser992Ter | p.S992* | Q9UKP5 | protein_coding | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ADAMTS6 | insertion | Nonsense_Mutation | novel | c.2979_2980insCCTCGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGC | p.Thr994ProfsTer12 | p.T994Pfs*12 | Q9UKP5 | protein_coding | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | ||
| ADAMTS6 | SNV | Missense_Mutation | novel | c.3239C>A | p.Thr1080Asn | p.T1080N | Q9UKP5 | protein_coding | tolerated(0.16) | benign(0.035) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ADAMTS6 | SNV | Missense_Mutation | c.190G>A | p.Asp64Asn | p.D64N | Q9UKP5 | protein_coding | tolerated(0.46) | benign(0.062) | TCGA-BI-A20A-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |